MedIntelliBase® NewsTips
April/May 2008
Your monthly newsletter from the
"better way to get and use market intelligence" people
MIB NewsTips...A Better stay up-to-date ...
Infant Weight & Heart Disease Risk...
CREATE Registry
May 6, 2008 – New Breaking News

Visitors can get free weekly clinical resuscitation abstracts through its Breaking News more.
Carotid Stenting vs. CEA-3-Year SAPPHIRE Results

April 10, 2008 - SAPPHIRE Trial results at 3 years are now in. CAS (carotid artery stenting) compared to CEA (carotid endarterectomy) produced no significant difference in long-term outcomes for patients with severe carotid artery stenosis.

The New England Journal of Medicine reported, "carotid stenting using distal embolic protection vs. carotid endarterectomy in patients at high surgical risk show no significant difference between groups in the prespecified secondary end point of the trial, a composite at 3 years of death, stroke, or myocardial infarction (MI) within 30 days of the procedure or death or ipsilateral stroke between 31 and 1080 days."
Read more...for more information on the SAPPHIRE Trial and its results. Or click on the thumbnail image above to view its MIB MarketTracks Clinical Trial summary.
According to a study presented at the American College of Cardiology’s Scientific Session 2008 --

"Low birth weight, especially in premature babies, has been associated with poor heart health in adulthood, resulting in the traditional view that rapid weight growth after birth may be protective. However, new evidence suggests that accelerated growth in preterm and term babies is associated with a range of diseases in later life, such as heart attack, diabetes and high blood pressure..." according to Marietta Charakida, M.D., Ph.D., of University College more.
ACC 2008 – 6-Month Interim Results

March 31, 2008 – First results from the CREATE Registry [Multi-Center Registry of Excel BiodegrAdable Polymer Drug EluTing StEnt] are now available.

CREATE Registry’s PI, Yaling Han MD, FSCAI Shenyang Northern Hospital, concluded that "6-month dual antiplatelet treatment seems safe after Excel stent implantation...Current data suggests a high degree of safety of the Excel biodegradable polymer coated SES, even though being used in ‘real world’ settings...Long-term (>1 yr) safety needs further investigation."
ZIPS Trial
(For an MIB MarketTracks summary of the CREATE Registry and its results click the thumbnail image above.)
CREATE, designed to assess the safety and efficacy of the ExcelTM biodegradable polymer coated sirolimus eluting stent in “real world” PCI practice, is produced by JWMS [Shandong Wuigao Group Medical - Weihai, China].

This registry examined stenting data from 2,077 patients enrolled in 59 locations in China, Indonesia, Malaysia and Thailand. The Excel biodegradable polymer sirolimus eluting stent has enjoyed strong sales in China over the last year following its approval in 2006.
Pathway Raises $24.5 Million...
April 15, 2008 - Pathway Medical Technologies Inc. [Kirkland WA] developer of medical devices used to treat arterial disease, reported it raised $24.5 million in a third round of financing which will help the company launch its first commercial product later this more.
MedIntelliBase Custom Alerts
MIB Custom Alerts...regularly pushed to you and your team
via email or RSS feeds.

Click on the image below to learn about our two-week free trial offer....
MIB Alert
MedIntelliBase Custom Alerts & MarketTracks...Your Competitive Advantage
MedIntelliBase-- A Better help you gain and retain your competitive advantage.

With MIB market intelligence services you find the critical clinical, technology and competitor medical market intelligence you need to make informed business decisions -- MIB is accessible online from wherever you are:
  • MIB Custom Alerts -- are highly customized intelligent search filters powered by "Human IntelligenceTM" that give you convenient, timely, and tightly focused updates on new developments in your industry segment -- pushed to you by RSS feeds and email at the frequency you demand.
  • MIB MarketTracks – are up-to-date and in-depth snapshot summaries of critical clinical trials and registries, and today’s emerging product technologies, searchable by trial name, technology or company – updates emailed as you need them.
  • MIB Alerts and MarketTracks are especially suitable for busy General Management, Marketing and Competitor Intelligence executives in medical device and biotechnology companies.
    MIB Custom Alerts & MarketTracks...are part of MedIntelliBase Medical Market Intelligence Tools:
    a set of vital tools for biotech and medical device executives, enabling you to gain and sustain a competitive advantage
    A Better get and use medical industry market intelligence.
    phone: 425.869.8724 • © 2008, The Next Phase, Inc.
    1. MedIntelliBase NewsTips is free and you are welcome to continue receiving it as long as you wish. If at any time you wish to cancel just click the Safe Unsubscribe link below.
    2. We will not share your name and e-mail address with anyone.
    3. Feel free to share or reproduce the information in this MedIntelliBase NewsTips e-newsletter (in whole or part) as long as proper mention and copyright notice is given to MedIntelliBase and The Next Phase**.
    4. If you are not the original recipient of this newsletter and would like to receive future issues, just click the Forward link below or drop us a line at MIBInfo@MedIntelliBase .com.

    Co-Editor: Vicky Hunsicker Sanko
    Phone - 425/869-8724

    Co Editor & Market Research Analyst: Jordan Zornes
    Phone - 425/894-4147
    Toll Free - 800/390-2756
    Fax - 866/381-6119

    MIB NewTips March 2008 Issue – Volume 3, Number 2

    **, © The Next Phase®, Inc. 2008. All rights reserved.